Although treatment models for schizophrenia have typically viewed the disease symptoms as progressing over time, research is now looking at the impact of pre-psychosis therapies for patients who may be at risk for developing schizophrenia.
With the availability of antipsychotic medication, the idea of recognizing and assessing patients before symptoms present has been revisited. Issues such as the younger age of prodromal cases and the impact that has on treatment regimens is evaluated, with general conclusions that untreated individuals still pose a higher risk of advanced disease.
Reference: Cornblatt BA, Auther AM. Treating early psychosis: who, what, and when?. Dialogues Clin Neurosci. 2005;7(1):39-49. doi:10.31887/DCNS.2005.7.1/bcornblatt